Stocktoria
Pharma Mar, S.A. PHM.MC
ES · Bolsa de Madrid · XMAD · stock · Healthcare · website
Pharma Mar, S.A. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €221.4M | €174.9M | €158.2M | €196.3M |
| Gross profit | €209.1M | €166.7M | €148.5M | €182.7M |
| R&D expense | €95.2M | €103.5M | €99.3M | €83.4M |
| SG&A expense | -€2.1M | -€2.7M | -€4.3M | €43.2M |
| Operating income | €60.0M | €6.0M | -€3.9M | €44.4M |
| Interest expense | €2.5M | €2.5M | €2.4M | €2.4M |
| Income tax | -€15.3M | -€14.1M | -€4.8M | -€5.6M |
| Net income | €75.0M | €26.1M | €1.1M | €49.4M |
| EPS (diluted) | €4.30 | €1.49 | €0.06 | €2.73 |
| Operating cash flow | €53.1M | €6.0M | -€13.4M | €38.3M |
| Free cash flow | €43.8M | -€9.5M | -€29.4M | €29.5M |
| Cash & equivalents | €17.8M | €63.2M | €60.0M | €149.8M |
| Inventory | €50.6M | €50.9M | €39.3M | €27.7M |
| Total assets | €395.1M | €349.6M | €340.5M | €393.3M |
| Total debt | €49.4M | €51.1M | €43.7M | €42.6M |
| Total liabilities | €143.2M | €141.3M | €147.1M | €170.3M |
| Shareholders' equity | €251.8M | €208.4M | €193.4M | €223.0M |
| Share buybacks | €34.1M | €18.7M | €37.9M | €50.2M |
Growth · year-over-year · Revenue CAGR 4.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +26.6% | +10.6% | -19.5% | — |
| Net income growth | +187.0% | +2197.7% | -97.7% | — |
| EPS growth | +188.6% | +2383.3% | -97.8% | — |
| Free cash flow growth | — | — | -199.8% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · ES · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.